Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date. Get alerts:Net revenue for the second quarter totaled $14.5 million, compared with $6.6 million in the same period of 2025. The Eon Care Network, which helps connect patients and prescribers with trained insertion providers, added 28 providers in the second quarter. For the full year, Senseonics continues to expect operating expenses of $150 million to $160 million and cash utilization of $110 million to $120 million. About Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes.